Search | OpenScholar

Search results

1498 results found

Efficacy and safety of botulinum type A toxin (Dysport) in cervical dystonia: results of the first US randomized, double-blind, placebo-controlled study. Movement Disorders 2005;20:783-791.

Publication: Journal Article

Truong, D, DD Duane, J Jankovic, C Singer, LC Seeberger, CL Comella, MF Lew, et al. 2005. “Efficacy and Safety of Botulinum Type A Toxin (Dysport) in Cervical Dystonia: Results of the First US Randomized, Double-Blind, Placebo-Controlled Study. Movement Disorders 2005;20:783-791.”. Movement Disorders.

A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease. Arch Neurol 2004;61:561-566.

Publication: Journal Article

Group, Parkinson Study. 2004. “A Controlled, Randomized, Delayed-Start Study of Rasagiline in Early Parkinson Disease. Arch Neurol 2004;61:561-566.”. Arch Neurol.

Heart failure in Parkinson's disease: analysis of the United States medicare current beneficiary survey. Parkinsonism Relat Disord 2004;10:417-420.

Publication: Journal Article

Zesiewicz, TA, JA Strom, AR Borenstein, RA Hauser, CR Cimino, H Fontanet, C Cintron, JF Staffetti, PB Dunne, and KL Sullivan. 2004. “Heart Failure in Parkinson’s Disease: Analysis of the United States Medicare Current Beneficiary Survey. Parkinsonism Relat Disord 2004;10:417-420.”. Parkinsonism Relat Disord.

Botulinum toxin A for the treatment of cervical dystonia. Expert Opin Pharmacother 2004;5:2017-2024.

Publication: Journal Article

Zesiewicz, TA, W Stamey, KL Sullivan, and RA Hauser. 2004. “Botulinum Toxin A for the Treatment of Cervical Dystonia. Expert Opin Pharmacother 2004;5:2017-2024.”. Expert Opin Pharmcother.

Adenosine A2A receptor antagonists for Parkinson’s disease: rationale, therapeutic potential and clinical experience. Drugs Aging. 2005;22:471-482.

Publication: Journal Article

Hauser, RA, and MA Schwarzchild. 2005. “Adenosine A2A Receptor Antagonists for Parkinson’s Disease: Rationale, Therapeutic Potential and Clinical Experience. Drugs Aging. 2005;22:471-482.”. Drugs Aging.

Levetiracetam for the treatment of essential tremor. Movement Disorders 2005; 20:640.

Publication: Journal Article

Sullivan, KL, RA Hauser, and TA Zesiewicz. 2005. “Levetiracetam for the Treatment of Essential Tremor. Movement Disorders 2005; 20:640.”. Movement Disorders.

Maha Ahmed joins the lab!

News: September 13, 2023

Maha is an undergraduate student at USF and used the word homeostasis when she interviewed. The start of a new promising kidney researcher!

Dr. Zietara awarded a T32 grant

News: November 01, 2024

Congrats Adrian!

Open-label pilot study of levetiracetam (Keppra) for the treatment of chorea in Huntington’s disease.

Publication: Journal Article

Zesiewicz, TA, KL Sullivan, RA Hauser, and J Sanchez-Ramos. 2006. “Open-Label Pilot Study of Levetiracetam (Keppra) for the Treatment of Chorea in Huntington’s Disease.”. Mov Disord.

The controversy concerning plasma homocysteine in Parkinson disease patients treated with levodopa alone or with entacapone: effects of vitamin status.

Publication: Journal Article

Zesiewicz, TA, L Wecker, KL Sullivan, LR Merlin, and RA Hauser. 2006. “The Controversy Concerning Plasma Homocysteine in Parkinson Disease Patients Treated With Levodopa Alone or With Entacapone: Effects of Vitamin Status.”. Clinical Neuropharmacology.